Another orally administrable, selective Syk inhibitor, BAY-61-3606, exhibits an inhibitory effect of degranulation and cytokine synthesis in mast cells and suppresses the symptoms of antigen-induced airway inflammation, including asthma and rhinitis, in in vivo animal models [96]. This evidence concerns the gene SYK and asthma.